JAMP-ZOLEDRONIC ACID SOLUTION

Country: Kanada

Bahasa: Inggeris

Sumber: Health Canada

Beli sekarang

Ciri produk Ciri produk (SPC)
07-11-2018

Bahan aktif:

ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE)

Boleh didapati daripada:

JAMP PHARMA CORPORATION

Kod ATC:

M05BA08

INN (Nama Antarabangsa):

ZOLEDRONIC ACID

Dos:

4MG

Borang farmaseutikal:

SOLUTION

Komposisi:

ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE) 4MG

Laluan pentadbiran:

INTRAVENOUS

Unit dalam pakej:

5 ML

Jenis preskripsi:

Prescription

Kawasan terapeutik:

BONE RESORPTION INHIBITORS

Ringkasan produk:

Active ingredient group (AIG) number: 0141761002; AHFS:

Status kebenaran:

APPROVED

Tarikh kebenaran:

2018-11-07

Ciri produk

                                PRODUCT MONOGRAPH
Pr
JAMP-ZOLEDRONIC ACID
(Zoledronic Acid for Injection)
4 mg Zoledronic acid/5 mL incorporated as the monohydrate
Sterile liquid concentrate must be diluted before use
Bone Metabolism Regulator
JAMP Pharma Corporation
Date of Preparation:
1310 Rue Nobel
November 7, 2018
Boucherville, Québec
J4B 5H3
Control # 220781
_Page 2 of 52_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE
REACTIONS..................................................................................................11
DRUG INTERACTIONS
..................................................................................................19
DOSAGE AND ADMINISTRATION
..............................................................................20
OVERDOSAGE
................................................................................................................23
ACTION AND CLINICAL PHARMACOLOGY
............................................................25
STORAGE AND STAB
IL
I
T
Y
..........................................................................................29
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................29
PART II: SCIENTIFIC
INFORMATION
...............................................................................30
PHARMACEUTICAL
INFORMATION..........................................................................30
CLINICAL
TR
IA
L
S
..........................................................................................................31
DETAILED PHARMACOLOGY
..
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Ciri produk Ciri produk Perancis 07-11-2018

Cari amaran yang berkaitan dengan produk ini